Source comparison
BPC-157 Ulcer Healing Results Timeline Expect: Research vs Clinical Evidence Comparison
| Model Type | Administration Route | Dose | Day 7 Healing | Day 14 Healing | Day 28 Healing | Bottom Line ||—|—|—|—|—|—|| Ethanol-Induced Gastric Ulcer | Subcutaneous | 10 µg/kg daily | 40–50% ulcer area reduction | 70–80% complete healing | 90–95% complete h
This comparison does not assign a generated winner or score.
- | Model Type | Administration Route | Dose | Day 7 Healing | Day 14 Healing | Day 28 Healing | Bottom Line ||—|—|—|—|—|—|| Ethanol-Induced Gastric Ulcer | Subcutaneous | 10 µg/kg daily | 40–50% ulcer area reduction | 70–80% complete healing | 90–95% complete healing | Fastest healing model. Acute injury with high angiogenic response || Acetic Acid Gastric Ulcer | Intraperitoneal | 10 µg/kg daily | 15–25% ulcer area reduction | 40–50% healing | 75–85% healing | Chronic injury model. Slower epithelial migration, requires sustained dosing || Cysteamine Duodenal Ulcer | Subcutaneous | 10 µg/kg daily | 30–40% ulcer index reduction | 58% ulcer index reduction | 82% ulcer index reduction | Closest to human peptic ulcer. Moderate healing kinetics || NSAID-Induced Gastric Ulcer | Oral | 10 mg/kg daily | 20–30% healing | 50–60% healing | 70–80% healing | Oral bioavailability lower. Requires 100–1000× dose vs injection || Stress-Induced Gastric Ulcer | Intraperitoneal | 10 µg/kg daily | 10–20% he